Save Studies Locally
We can save your selected studies locally in your browser to enhance your experience. This data stays on your device and is not shared with us or third parties. You can clear this data at any time.
By allowing this, you consent to storing study selections locally on your device. Privacy Policy
How to Navigate Ecosystem Connect NEWDistinguished Investigators Global Conferences RLT Education RLT Components Sponsors Trial Stats
177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer
Description:
This phase 1 dose-escalation and dose-expansion study is designed to evaluate the safety and tolerability of olaparib in combination with 177Lutetium-Prostate Specific Membrane Antigen (177 Lu-PSMA) in patients with metastatic castration resistant prostate cancer (mCRPC).
Sponsor:
Peter MacCallum Cancer Centre
Contacts:
Shahneen Sandhushahneen.sandhu@petermac.org
+61 3 8559 7902
Michael Hofmanmichael.hofman@petermac.org
+61 3 8559 6914
Government Study Link:
NCT03874884 - Click here to see study onClinicalTrials.gov
